Cargando…

Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome

OBJECTIVE: To assess whether neoadjuvant chemotherapy (NACT) is superior to primary debulking surgery (PDS) with regard to optimal cytoreduction, peri-operative morbidity, mortality, and quality of life (QOL) in advanced epithelial ovarian cancer (EOC). METHODS: We searched the PubMed, Embase, Cochr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Lijuan, Zhang, Bo, Xing, Guangyang, Du, Jingran, Yang, Bin, Yuan, Qianqian, Yang, Yongxiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653345/ https://www.ncbi.nlm.nih.gov/pubmed/29059209 http://dx.doi.org/10.1371/journal.pone.0186725

Ejemplares similares

Expression of Concern: Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome
Publicado: (2023)

Role of Neoadjuvant Chemotherapy in Ovarian Serous Cancer Followed by Debulking
por: Chauhan, Sonali, et al.
Publicado: (2022)

The prognostic effect of residual tumor for advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy or primary debulking surgery
por: Yang, Shi‐Ping, et al.
Publicado: (2022)

Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study
por: Nagao, Shoji, et al.
Publicado: (2023)

Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study
por: Liu, Xingyu, et al.
Publicado: (2023)

Efficacy and safety of neoadjuvant chemotherapy versus primary debulking surgery in patients with ovarian cancer: a meta-analysis
por: Lv, Xiaofeng, et al.
Publicado: (2019)

The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with ovarian cancer
por: Vitarello, John, et al.
Publicado: (2021)

Quinary debulking for epithelial ovarian cancer
por: Edwards, James M., et al.
Publicado: (2012)

Primary Debulking Surgery Versus Primary Neoadjuvant Chemotherapy for High Grade Advanced Stage Ovarian Cancer: Comparison of Survivals
por: Kobal, Borut, et al.
Publicado: (2018)

Comparison of Survival Between Primary Debulking Surgery Versus Neoadjuvant Chemotherapy for Ovarian Cancers in a Personalized Treatment Cohort
por: Feng, Zheng, et al.
Publicado: (2021)

Cost-effectiveness of primary debulking surgery when compared to neoadjuvant chemotherapy in the management of stage IIIC and IV epithelial ovarian cancer
por: Forde, Gareth K, et al.
Publicado: (2016)

Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery
por: Liu, Ying L., et al.
Publicado: (2019)

Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?
por: Yoneoka, Yutaka, et al.
Publicado: (2019)

Neoadjuvant Chemotherapy Versus Primary Debulking Surgery in FIGO Stage III and IV Epithelial Ovarian, Tubal or Peritoneal Cancer: A Systematic Review and Meta-Analysis
por: Tzanis, Alexander A., et al.
Publicado: (2022)

Model for Prediction of Optimal Debulking of Epithelial Ovarian Cancer
por: Arab, Maliheh, et al.
Publicado: (2018)

Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Lee, Yong Jae, et al.
Publicado: (2020)

Role of Lymphadenectomy During Interval Debulking Surgery Performed After Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer
por: He, Minjun, et al.
Publicado: (2021)

Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival?
por: Menczer, Joseph, et al.
Publicado: (2011)

A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer
por: Park, Junsik, et al.
Publicado: (2020)

Residual tumor and primary debulking surgery vs interval debulking surgery in stage IV epithelial ovarian cancer
por: Sørensen, Sarah Mejer, et al.
Publicado: (2022)

No obvious advantage of hyperthermic intraperitoneal chemotherapy after interval debulking surgery in the treatment of advanced ovarian cancer: A retrospective study
por: Lyu, Mengmeng, et al.
Publicado: (2022)

Negative peritoneal washing cytology during interval debulking surgery predicts overall survival after neoadjuvant chemotherapy for ovarian cancer
por: Iura, Ayaka, et al.
Publicado: (2018)

Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer
por: Andrikopoulou, Angeliki, et al.
Publicado: (2023)

Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
por: Lin, Hao, et al.
Publicado: (2021)

Factors associated with surgical morbidity of primary debulking in epithelial ovarian cancer
por: Günakan, Emre, et al.
Publicado: (2020)

Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer [Corrigendum]
Publicado: (2021)

Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept
por: Jiang, Rong, et al.
Publicado: (2020)

Post-operative residual disease and number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma
por: Perrone, Anna Myriam, et al.
Publicado: (2023)

Optimal number of neoadjuvant chemotherapy cycles prior to interval debulking surgery in advanced epithelial ovarian cancer: a systematic review and meta-analysis of progression-free survival and overall survival
por: Coada, Camelia Alexandra, et al.
Publicado: (2023)

CA-125 cut-off value as a predictor for complete interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer
por: Furukawa, Naoto, et al.
Publicado: (2013)

Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer—A National Cancer Database Study
por: Leiserowitz, Gary S., et al.
Publicado: (2017)

Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy
por: Lyons, Yasmin A, et al.
Publicado: (2020)

Diagnosis and preoperative predictive value of serum HE4 concentrations for optimal debulking in epithelial ovarian cancer
por: YANG, ZHIJUN, et al.
Publicado: (2013)

The added value of CA125 normalization before interval debulking surgery to the chemotherapy response score for the prognostication of ovarian cancer patients receiving neoadjuvant chemotherapy for advanced disease
por: Liang, Wei-feng, et al.
Publicado: (2021)

Incidence of venous thromboembolism following the neoadjuvant chemotherapy regimen for epithelial type of ovarian cancer
por: Chavan, Devendra Manik, et al.
Publicado: (2017)

Efficacy and Safety of Minimally Invasive Surgery Versus Open Laparotomy for Interval Debulking Surgery of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy: A Systematic Review and A Meta-Analysis
por: Zeng, Siyuan, et al.
Publicado: (2022)

Nadir CA-125 serum levels during neoadjuvant chemotherapy and no residual tumor at interval debulking surgery predict prognosis in advanced stage ovarian cancer
por: Nakamura, Kazuto, et al.
Publicado: (2020)

Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced‐stage ovarian cancer
por: Huang, Chueh‐Yi, et al.
Publicado: (2020)

The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies
por: Qin, Meng, et al.
Publicado: (2017)

Incorporation of paclitaxel-based hyperthermic intraperitoneal chemotherapy in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery: a protocol-based pilot study
por: Lee, Yong Jae, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_smkvir35ta34dl2mb319knvtvj